MyStocks

MEMBER'S LOGINX

Remember Username
Keep me signed in

(Please do not use this option on a public machine)

Home
Research It
Compare Company
International - indian pharma
CADILA HEALTHCARE - MYLAN (US)

CADILA HEALTHCARE vs MYLAN (US) - Comparison Results

Mail
Print
FaceBook
Twitter
Linked In
WhatsApp

CADILA HEALTHCARE Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

MYLAN (US)
Change

Mylan is one of the world�s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry�s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

CADILA HEALTHCARE

MYLAN

EQUITY SHARE DATA
		CADILA HEALTHCARE Mar-20	MYLAN Dec-18	CADILA HEALTHCARE/ MYLAN	5-Yr Chart Click to enlarge
High	Rs	352	3,474	-
Low	Rs	207	1,912	-
Sales per share (Unadj.)	Rs	139.2	1,598.5	-
Earnings per share (Unadj.)	Rs	11.8	43.4	-
Cash flow per share (Unadj.)	Rs	18.6	342.7	-
Dividends per share (Unadj.)	Rs	3.50	0	-
Dividend yield (eoy)	%	1.3	0	-
Book value per share (Unadj.)	Rs	101.4	1,729.3	-
Shares outstanding (eoy)	m	1,023.74	514.50	-
Bonus/Rights/Conversions		-	-	-
Price / Sales ratio	x	2.0	1.7	119.1%
Avg P/E ratio	x	23.7	62.0	38.3%
P/CF ratio (eoy)	x	15.0	7.9	191.5%
Price / Book Value ratio	x	2.8	1.6	177.0%
Dividend payout	%	29.8	0	-
Avg Mkt Cap	Rs m	286,033	1,385,529	20.6%
No. of employees	`000	13.4	35.0	38.3%
Total wages/salary	Rs m	24,145	0	-
Avg. sales/employee	Rs Th	10,632.7	23,497.5	45.3%
Avg. wages/employee	Rs Th	1,801.2	0	-
Avg. net profit/employee	Rs Th	898.5	638.1	140.8%

INCOME DATA
Net Sales	Rs m	142,531	822,412	17.3%
Other income	Rs m	1,139	0	-
Total revenues	Rs m	143,670	822,412	17.5%
Gross profit	Rs m	24,198	212,810	11.4%
Depreciation	Rs m	6,965	153,988	4.5%
Interest	Rs m	3,418	39,555	8.6%
Profit before tax	Rs m	14,954	19,267	77.6%
Minority Interest	Rs m	288	0	-
Prior Period Items	Rs m	0	0	-
Extraordinary Inc (Exp)	Rs m	0	0	-
Tax	Rs m	3,198	-3,065	-104.3%
Profit after tax	Rs m	12,044	22,332	53.9%
Gross profit margin	%	17.0	25.9	65.6%
Effective tax rate	%	21.4	-15.9	-134.4%
Net profit margin	%	8.5	2.7	311.2%

BALANCE SHEET DATA
Current assets	Rs m	87,154	459,234	19.0%
Current liabilities	Rs m	82,694	334,832	24.7%
Net working cap to sales	%	3.1	15.1	20.7%
Current ratio	x	1.1	1.4	76.8%
Inventory Days	Days	71	84	85.5%
Debtors Days	Days	94	93	100.5%
Net fixed assets	Rs m	133,236	159,534	83.5%
Share capital	Rs m	1,024	438	233.9%
"Free" reserves	Rs m	102,733	0	-
Net worth	Rs m	103,757	889,699	11.7%
Long term debt	Rs m	32,146	960,271	3.3%
Total assets	Rs m	236,866	2,386,519	9.9%
Interest coverage	x	5.4	1.5	361.5%
Debt to equity ratio	x	0.3	1.1	28.7%
Sales to assets ratio	x	0.6	0.3	174.6%
Return on assets	%	6.5	2.6	251.7%
Return on equity	%	11.6	2.5	462.5%
Return on capital	%	13.7	3.2	431.8%
Exports to sales	%	0	0	-
Imports to sales	%	0	0	-
Net fx	Rs m	38,248	0	-

CASH FLOW
From Operations	Rs m	25,054	170,897	14.7%
From Investments	Rs m	-10,123	-88,335	11.5%
From Financial Activity	Rs m	-10,942	-79,614	13.7%
Net Cashflow	Rs m	3,989	1,416	281.7%

NM: Not Meaningful

Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 72.98 Rs / USD

Compare CADILA HEALTHCARE With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)

Compare CADILA HEALTHCARE With: ALEMBIC PHARMA UNICHEM LAB STRIDES PHARMA SCIENCE AJANTA PHARMA DISHMAN PHARMA

Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.